@thelancetinfdis.bsky.social
The Lancet Infectious Diseases is the leading clinical infectious diseases journal for peer-reviewed research and review, comment, and news.
@thelancetinfdis.bsky.socialNew Personal View
When the fungus is susceptible, but the patient is not: reading antifungal susceptibility from bench to bedside
@lancetmicrobe.bsky.socialReposted by @thelancetinfdis.bsky.socialNew research article
Regional expansion and adaptive evolution of multidrug-resistant #Candida tropicalis in China: a retrospective, multicentre, genomic study
@thelancetinfdis.bsky.socialNew Research
Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study
@lancetrh-europe.bsky.socialReposted by @thelancetinfdis.bsky.socialWhat is the real-world impact of HPV vaccination in Germany?
Using Bavarian health claims and prescription data from 669,053 women, this study found full vaccination was associated with a 65% lower adjusted risk of invasive cervical cancer.
Read more 👇
shorturl.at/Cjxcy
@lancetmicrobe.bsky.socialReposted by @thelancetinfdis.bsky.socialOur October issue is now online:
www.thelancet.com/journals/lan...
Our journal is #OpenAccess, so you are free to explore all of our content. But these hashtags offer a flavour: #AMR #influenza #Streptococcus #Shigella #melioidosis #tuberculosis
@thelancetinfdis.bsky.social@thelancetinfdis.bsky.socialNew Research
Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, evaluated with and without tetanus-reduced diphtheria-acellular pertussis vaccine in healthy children: a randomised, active-controlled and placebo-controlled, phase 2b trial
@lancetmicrobe.bsky.socialReposted by @thelancetinfdis.bsky.socialNew research article
Epidemiology and phylogenomic characterisation of the 2025 #Ebola virus disease outbreak in Bulape, Kasaï province, Democratic Republic of the Congo: a retrospective observational study
@thelancetinfdis.bsky.socialNew Review
Methodological quality and risk of bias in non-randomised comparative effectiveness studies of invasive mould infections: a systematic review
@eclinicalmed.bsky.socialReposted by @thelancetinfdis.bsky.socialGlobal, regional, and national burden of #tetanus in 204 countries and territories, 1990–2023: analysis for the GBD Study 2023
Over the past 3 decades, global initiatives such as EPI and MNTE have led to a substantial reduction in the burden of tetanus
@thelancetinfdis.bsky.socialRead our October issue, live now!
Featuring a new regimen with quabodepistat for tuberculosis, oral care for preventing hospital-acquired pneumonia, and tocilizumab for severe hantavirus pulmonary syndrome.
@thelancetinfdis.bsky.socialNew Research
Efficacy and safety of alternative benznidazole and nifurtimox regimens for adults with chronic Trypanosoma cruzi infection (TESEO): an open-label, randomised, non-inferiority phase 2b trial
@lancetmicrobe.bsky.socialReposted by @thelancetinfdis.bsky.socialNew research article
Evaluation of the effect of serotype on pneumococcal conjugate #vaccine induced immunity: an exploratory analysis of the PREVENTING PNEUMO 2 trial
@thelancetinfdis.bsky.socialRecalibrating quantitative PCR cycle-thresholds could improve mpox diagnostic accuracy in high-transmission settings
@thelancetinfdis.bsky.socialNew Research
The risk of mpox false positive results in high transmission settings: evidence from a multi-site observational study in DR Congo
@thelancetinfdis.bsky.social@thelancetinfdis.bsky.socialNew Research
Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial
@thelancetinfdis.bsky.socialNew Personal View
Is a tiered classification framework needed for sexually transmitted infections?
@thelancetinfdis.bsky.socialNew Comment
South Sudan's first 100 days of Bundibugyo Ebola readiness
@thelancetinfdis.bsky.socialNew Review
Nucleic acid amplification testing and genome sequencing for WHO priority viruses in Africa: a scoping review
